News Center
News Type
The Phase III Clinical Study of China’s First Novel Anti-Infection Drug, Masorasavir Tablets, Published in Prestigious International Journal
On January 7, 2025, the Phase III clinical trial results for Suraxavir Marboxil Tablets, a Class 1 innovative drug developed by Qingfeng Pharmaceutical, were published in Nature Medicine (Impact Factor: 58.7).
Qingfeng will attend the 2025 J.P. Morgan Healthcare Conference
Qingfeng Pharmaceutical Group, will attend “The 43rd Annual J.P. Morgan Healthcare Conference” in San Francisco, from January 13-16, 2025.
7 Qingfeng Pharmaceutical Products Win Bids at the 10th National Drug Centralized Procurement
On December 12, the bidding for the 10th batch of the National Organized Drug Centralized Procurement officially began.
Great News! Two Qingfeng Pharmaceutical Products Included in the 2024 National Medical Insurance Catalog
On November 28, the National Healthcare Security Administration (NHSA) announced the results of the 2024 adjustments to the National Medical Insurance Drug List. Qingfeng Pharmaceutical’s Aurantii Fructus Immaturus Total Flavonoids tablets and QingRuiTan® Brivaracetam Tablets were officially included.
Qingfeng Pharmaceutical's First Shipment of Ibrutinib Mesylate Injection Exported to the U.S.
At 11:18 AM on October 25, 2024, the shipment ceremony for Qingfeng Pharmaceutical's Ibrutinib Mesylate Injection for export to the United States was held in Chengdu, marking a significant milestone in the company’s international journey.
56th Place! Qingfeng Pharmaceutical Ranks Once Again in China's top 100 Pharmaceutical Industry
On September 7, 2024, the 41st National Pharmaceutical Industry Information Annual Conference opened in Chengdu, Sichuan. At the conference, the Ministry of Industry and Information Technology released its highly anticipated 2023 “China's top 100 Pharmaceutical Industry”, with Qingfeng Pharmaceutical ranking 56th, up 24 spots from last year.
